Eagle Pharmaceuticals, Inc.
EGRX
$1.90
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Net Income | 11.95M | -2.67M | 35.64M | 21.28M | 22.79M |
| Total Depreciation and Amortization | 21.92M | 17.96M | 13.27M | 8.66M | 5.64M |
| Total Amortization of Deferred Charges | 459.00K | 464.00K | 469.00K | 472.00K | 472.00K |
| Total Other Non-Cash Items | 13.99M | 16.73M | 17.73M | 31.51M | 20.12M |
| Change in Net Operating Assets | -57.64M | 1.31M | -16.40M | -40.69M | -13.50M |
| Cash from Operations | -9.32M | 33.80M | 50.70M | 21.23M | 35.53M |
| Capital Expenditure | -74.00K | -68.00K | -178.00K | -217.00K | -222.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 1.26M | -74.15M | -74.15M | -74.15M | -75.42M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -25.00M | -25.00M | -12.50M | -12.50M | 0.00 |
| Cash from Investing | -23.81M | -99.22M | -86.83M | -86.87M | -75.64M |
| Total Debt Issued | 110.00M | 95.00M | 80.00M | 15.00M | -- |
| Total Debt Repaid | -85.74M | -66.49M | -67.24M | -8.00M | -8.00M |
| Issuance of Common Stock | 247.00K | 1.75M | 1.75M | 2.30M | 2.29M |
| Repurchase of Common Stock | -11.23M | -11.11M | -19.36M | -28.02M | -26.34M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.36M | -1.36M | -1.36M | -- | -- |
| Cash from Financing | 11.92M | 17.80M | -6.21M | -18.71M | -32.05M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -21.21M | -47.63M | -42.34M | -84.36M | -72.16M |